Literature DB >> 21813530

Current approach to the diagnosis of acute nonmassive pulmonary embolism.

Lisa K Moores1, Christopher S King2, Aaron B Holley3.   

Abstract

Pulmonary embolism is a common and potentially lethal disease. Given the variable presentation and associated morbidity of this condition, an accurate and efficient diagnostic algorithm is required. Clinical pretest probability serves as the root of any diagnostic approach. We, thus, review several clinical decision rules that may help standardize this determination. Using a review of the literature, the accuracy, predictive values, and likelihood ratios for several diagnostic tests are described. The combination of these tests, based on the pretest probability of disease, can be used in a Bayesian fashion to make accurate treatment decisions. A completely noninvasive diagnostic algorithm for patients presenting with suspected acute pulmonary embolism is proposed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21813530     DOI: 10.1378/chest.10-2468

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  3 in total

1.  Clinical usefulness and safety of an age-adjusted D-dimer cutoff levels to exclude pulmonary embolism: a retrospective analysis.

Authors:  Julio Flores; Jaime García de Tena; Javier Galipienzo; Ángel García-Avello; Esteban Pérez-Rodríguez; José Ignacio Tortuero; Concepción Álvarez; Antonio Ruíz; Ignacio Arribas
Journal:  Intern Emerg Med       Date:  2015-09-07       Impact factor: 3.397

2.  Serum microRNA-1233 is a specific biomarker for diagnosing acute pulmonary embolism.

Authors:  Thorsten Kessler; Jeanette Erdmann; Baiba Vilne; Petra Bruse; Volkhard Kurowski; Patrick Diemert; Heribert Schunkert; Hendrik B Sager
Journal:  J Transl Med       Date:  2016-05-05       Impact factor: 5.531

3.  Finding an alternative diagnosis does not justify increased use of CT-pulmonary angiography.

Authors:  Subani Chandra; Pralay K Sarkar; Divay Chandra; Nicole E Ginsberg; Rubin I Cohen
Journal:  BMC Pulm Med       Date:  2013-02-07       Impact factor: 3.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.